3rd Quarter - Report

PRIME THERAPEUTICS for PRIME THERAPEUTICS

Firm
Client
Income
—
Expenses
$50,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S.524: Comprehensive Addiction and Recovery Act, focused on Prescription Drug Management Plans (PDMPs), Medicare lock-ins, partial fills and co-prescribing. S.480/H.R.1725: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015, educating on the importance of PDMPs and the need for federal funding. HR.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act. H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016. S.2256: Co-Prescribing Saves Lives Act of 2016. S.1945: Senate HELP mental health reform package, Mental Health Reform Act of 2016, mental health parity treatment of step therapy and prior-authorization. S.2615: Increasing Competition in Pharmaceuticals Act, support increasing generic availability. H.R.6: The 21st Century Cures Act and Senate companions, ensuring no new barriers to generic and biosimilar market entry. Generic Drug User Fee Act Reauthorization, support increasing generic availability. H.R.1600: The Patients' Access to Treatment Act, educating on the importance of step therapy to ensuring optimal therapy access and cost control. H.R.2841: the FAST Generics Act. S.3056: the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S.2700: Workforce Authorities Modernization Act, Section 11, Biological Product Innovation - treatment of USP compendia in approving biologics and biosimilars. Role of PBMs in Mylan pricing before Congressional hearings/investigation of Mylan. Drug pricing in general. H.R.6043 and S.3335, "Fair Accountability and Innovative Research Drug Pricing Act of 2016".

LobbyistCovered position, as disclosed
JULIE CAROL CANTOR-WEINBERG —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 6043 (114th), H.R. 2841 (114th), S. 1945 (114th), S. 2700 (114th), H.R. 3680 (114th), H.R. 4981 (114th), H.R. 6 (114th), S. 3056 (114th), S. 524 (114th), S. 3335 (114th), S. 2615 (114th), S. 2256 (114th), S. 480 (114th), H.R. 1600 (114th), H.R. 1725 (114th), H.R. 4599 (114th), S. 2578 (114th)

Medicare/Medicaid MMM

Potential future guidance on DIR: Direct and Indirect Renumeration for Pharmacies. S.524: "Comprehensive Addiction and Recovery Act," focused on Prescription Drug Management Plans (PDMPs). S.480/H.R.1725: "National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015," educating on the importance of PDMPs and the need for federal funding. H.R.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act. H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016. S.2256: Co-Prescribing Saves Lives Act of 2016. H.R.244: "MAC Transparency Act," educating on how MAC pricing helps control costs for consumers. H.R.793/S.1190: "Ensuring Seniors Access to Local Pharmacies Act of 2015," importance of pharmacy networks in reducing costs. H.R.1600: "The Patients' Access to Treatment Act," educating on the importance of step therapy to ensuring optimal therapy access and cost control. Drug pricing in general. H.R.5951 and S.3308, Improving Transparency and Accuracy in Medicare Part D Spending Act.

LobbyistCovered position, as disclosed
JULIE CAROL CANTOR-WEINBERG —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 480 (114th), H.R. 1725 (114th), S. 524 (114th), S. 2256 (114th), H.R. 4599 (114th), H.R. 793 (114th), H.R. 5951 (114th), H.R. 4981 (114th), H.R. 244 (114th), H.R. 1600 (114th), S. 1190 (114th), H.R. 3680 (114th), S. 2578 (114th), S. 3308 (114th)

Pharmacy PHA

S.524: Comprehensive Addiction and Recovery Act, focused on Prescription Drug Management Plans (PDMPs), Medicare lock-in, partial fills and co-prescribing. S.480/H.R.1725: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015, educating on the importance of PDMPs and the need for federal funding. H.R.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act. H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016. S.2256: Co-Prescribing Saves Lives Act of 2016. H.R.4784: Lower Drug Costs Through Competition Act, support increasing generic availability. S.2680: A bill to amend the Public Health Service Act to provide comprehensive mental health reform, and for other purposes. S.2615: the Increasing Competition in Pharmaceuticals Act.

LobbyistCovered position, as disclosed
JULIE CAROL CANTOR-WEINBERG —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3680 (114th), S. 2680 (114th), S. 2615 (114th), H.R. 4981 (114th), S. 2256 (114th), S. 2578 (114th), S. 524 (114th), H.R. 4599 (114th), S. 480 (114th), H.R. 4784 (114th), H.R. 1725 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.